<DOC>
	<DOC>NCT01116830</DOC>
	<brief_summary>This randomized, double-blind, placebo-controlled parallel group study will assess the effect on biomarkers measures of cognitive dysfunction, the clinical efficacy and safety of RO4917838 in participants with schizophrenia and schizoaffective disorder. Participants will be randomized to receive either RO4917838 (10 milligrams [mg] daily orally) or placebo for 6 weeks, in addition to their stable antipsychotic medication. Anticipated time on study treatment is 6 weeks.</brief_summary>
	<brief_title>A Study of the Effect of RO4917838 on Biomarker Measures of Cognitive Dysfunction in Participants With Schizophrenia and Schizoaffective Disorder</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Antipsychotic Agents</mesh_term>
	<criteria>Diagnosis of schizophrenia or schizoaffective disorder (based on screening tests) Medically stable for 1 month and psychiatrically stable without symptom exacerbation for 6 weeks prior to baseline On stable treatment with a maximum of 2 antipsychotics Change in regimen for any psychotropic or sleep medication within 1 month Treatment with more than (&gt;) 1 mood stabilizer or antidepressant Use of clozapine within 2 months Bipolar disorder, or more than mild anxiety disorder</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>